Author:
Basile Anthony S.,Lippa Arnold S.,Skolnick Phil
Subject
Drug Discovery,Pharmacology,Molecular Medicine
Reference51 articles.
1. Don’t ask, don’t tell, but benzodiazepines are still the leading treatments for anxiety disorder;Stahl;J. Clin. Psych.,2002
2. International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders;Uhlenhuth;J. Clin. Psychopharmacol.,1999
3. Pharmacological agents acting at subtypes of metabotropic glutamate receptors;Schoepp;Neuropharmacol.,1999
4. Anxiolytic properties of the selective, non-peptidergic CRF(1) antagonists, CP154,526 and DMP695: a comparison to other classes of anxiolytic agent;Millan;Neuropsychopharmacol.,2001
5. Pharmacology and neurochemistry of buspirone;Riblet;J. Clin. Psych.,1982
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synthesis of Highly Functionalized Imidazopyridine: A Simple One-Pot Three-Component Synthesis of 6-Hydroxy-5 -(3-Phenylimidazo[1,2-
a
]Pyridin-2-yl)-2-Thioxo-2, 3-Dihydropyrimidin-4(1H)-Ones;Polycyclic Aromatic Compounds;2023-01-11
2. Rational approaches for the design of various GABA modulators and their clinical progression;Molecular Diversity;2020-03-13
3. Antiprotozoal agents as water soluble singlet oxygen photosensitizers: Imidazo[1,2-a]pyridine and 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine derivatives;Journal of Luminescence;2017-01
4. A Multicenter, Placebo-Controlled, Double-Blind, Randomized Study of Efficacy and Safety of Ocinaplon (DOV 273,547) in Generalized Anxiety Disorder;CNS Neuroscience & Therapeutics;2010-04
5. Development of Subtype-Selective GABAA Receptor Compounds for the Treatment of Anxiety, Sleep Disorders and Epilepsy;GABA and Sleep;2010